Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Basic Sciences

Late Target Protein of the Carcinogen N-2-Fluorenylacetamide in Rat Liver

Khan M. Munir, Gary R. Blackburn and Sam Sorof
Khan M. Munir
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gary R. Blackburn
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam Sorof
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published December 1988
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

In previous studies, administration of a radioactive tracer dose of the liver carcinogen, N-2-fluorenylacetamide (2-acetylaminofluorene; FAA), to normal or carcinogen-fed rats led to the presence of one or two principal labeled carcinogen:protein complexes in liver cytosol. The early target Mr 14,000 protein of the carcinogen in normal rats was identified as being liver fatty acid-binding protein and was associated in hepatocytes with normal mitosis and the cell proliferation brought about by either of the two liver carcinogens, FAA or 3′-methyl-4-dimethylaminoazobenzene. Continued ingestion of any of the three hepatocarcinogens, FAA, 3′-methyl-4-dimethylaminoazobenzene, or ethionine, resulted in the progressive loss of the early radioactive complex and the concurrent gain in liver cytosol of the late carcinogen:protein complex (Mr ∼150,000) formed by the tracer dose of FAA.

Present attempts to extract FAA derivatives from the late carcinogen:protein complex with organic solvents indicated that virtually all of the carcinogen was apparently covalently bound to the resultant denatured protein. It is unknown whether the covalent interaction occurred in vivo or as an accompaniment of the protein denaturation associated with the solvent extractions. In support of a possible noncovalent interaction, treatment of the unextracted complex with sodium dodecyl sulfate, urea, and β-mercaptoethanol followed by electrophoresis readily dissociated the majority of the bound carcinogen. The late carcinogen:protein complex was shown to contain a 55 kDa subunit (p55), which was purified to homogeneity according to molecular size. The subunit is a relatively basic polypeptide with a pI of 8.4 to 8.6. In Western blots using rabbit immunoglobulins against the p55, the late target protein was found to be present at low concentrations in liver cytosols of normal rats, and was induced to relatively high levels by ingestion of the carcinogen for 3 to 5 weeks. The induction of high levels of the late target protein explains in part the progressive elevation in content of the late carcinogen:protein complex in rat liver during carcinogenesis by FAA. The isolated p55 was susceptible to a spontaneous stepwise breakdown, resulting in a ladder of decreasing molecular sizes with an average unit difference of 5.8 kDa per step over six size intervals. The p55 subunit was detected in nonhepatic organs of normal rats, but unlike levels in liver, the levels there were not affected by ingestion of the carcinogen. The purification of the p55 subunit and preparation of its immunoglobulins provide the basis of future studies on the functional roles of the late target protein and its relationships to the early target protein in hepatocytes.

Footnotes

  • ↵1 This investigation was supported by NIH Grants CA-05945, CA-06927, and RR-05539 and an appropriation from the Commonwealth of Pennsylvania.

  • ↵3 To whom requests for reprints should be addressed.

  • Received April 27, 1988.
  • Revision received August 12, 1988.
  • Accepted September 2, 1988.
  • ©1988 American Association for Cancer Research.
PreviousNext
Back to top
December 1988
Volume 48, Issue 23
  • Table of Contents
  • Table of Contents (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Late Target Protein of the Carcinogen N-2-Fluorenylacetamide in Rat Liver
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Late Target Protein of the Carcinogen N-2-Fluorenylacetamide in Rat Liver
Khan M. Munir, Gary R. Blackburn and Sam Sorof
Cancer Res December 1 1988 (48) (23) 6745-6752;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Late Target Protein of the Carcinogen N-2-Fluorenylacetamide in Rat Liver
Khan M. Munir, Gary R. Blackburn and Sam Sorof
Cancer Res December 1 1988 (48) (23) 6745-6752;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Basic Sciences

  • Differential Expression of Transforming Growth Factor-β1 Gene in 3LL Metastatic Variants
  • Extracellular Matrix and the Patterns of Differentiation of Human Endometrial Carcinomas in Vitro and in Vivo
  • O6-Methylguanine Is a Critical Determinant of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Tumorigenesis in A/J Mouse Lung
Show more Basic Sciences

Articles

  • Differential Expression of Transforming Growth Factor-β1 Gene in 3LL Metastatic Variants
  • Extracellular Matrix and the Patterns of Differentiation of Human Endometrial Carcinomas in Vitro and in Vivo
  • O6-Methylguanine Is a Critical Determinant of 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Tumorigenesis in A/J Mouse Lung
Show more Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement